Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. METHODS: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). RESULTS: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. CONCLUSIONS: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subset of those suffering from Major Depressive Disorder (MDD) achieve remission with antidepressant medication (ADM)1.”
From The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse (2020) · cites this paper as [1]
In the citing paper
“about onethird receive no benefit from two or more pharmacologic treatments (Rush et al., 2006;Trivedi et al., 2006).”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Rush et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationCUMULATIVE ILLNESS RATING SCALE
LINN, B. S., LINN, M. W., & GUREL, L. (1968) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1968.tb02103.x · Cited by 2,304
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Self-citationAgency for Health Care Policy and Research
Eisenberg, J. M. (1999) · Medical Care · doi:10.1097/00005650-199903000-00001 · Cited by 1,369
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citation
Research works printed but not linked: 4
- Agency for Health Care Policy and Research. Depression in primary care. Vol. 2. Treatment of major depression. Rockville, Md.: Department of Health and Human Services, 1993. (AHCPR publication no. 93-0551.)
- Fava M, 2000, J Clin Psychiatry, 61, 10
- Joffe RT, 1996, J Clin Psychiatry, 57, 114
- Fava M, 2003, Ann Clin Psychiatry, 15, 17, 10.3109/10401230309085666 · doi:10.3109/10401230309085666 · Paper page
Cited by
Items 501–600 of 999
Entropy Learning for Dynamic Treatment Regimes
Jiang, B.-Y., Song, R., Li, J.-L., & Zeng, D. (2019) · Statistica sinica · doi:10.5705/ss.202018.0076 · Cited by 25
Brunoni, A. R., Santos, I. S., Passos, I. C., Goulart, A. C., Koyanagi, A., Carvalho, A. F., Barreto, S. M., Viana, M. C., Lotufo, P. A., & Benseñor, I. M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.155 · Cited by 27
Strawn, J. R., Aaronson, S. T., Elmaadawi, A. Z., Schrodt, G. R., Holbert, R. C., Verdoliva, S., Heart, K. L., Demitrack, M. A., & Croarkin, P. E. (2020) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2020.0008 · Cited by 24
“There have been divergent approaches, but, in recent years, the Antidepressant Treatment History Form (ATHF) has become the most common instrument to categorize the degree of treatment resistance in adults and has been used in studies of electroconvulsive therapy, transcranial magnetic stimulation (TMS), TRD, and sequ…”
ResultJones, C., & Nemeroff, C. B. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_27 · Cited by 28
Funk, A. P., & George, M. S. (2008) · Clinical EEG and Neuroscience · doi:10.1177/155005940803900306 · Cited by 22
Soini, E. J., Hallinen, T., Brignone, M., Campbell, R., Diamand, F., Cure, S., Aalto-Setälä, M., Danchenko, N., Koponen, H., & Kolasa, K. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2017.1240617 · Cited by 22
“[23] presents rates, these values were converted to probabilities for this model.”
BackgroundMethodManagement of access to branded psychotropic medications in private health plans
Hodgkin, D., Horgan, C. M., Garnick, D. W., Merrick, E. L., & Volpe-Vartanian, J. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.02.011 · Cited by 20
Nemeroff, C. B. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18010014 · Cited by 19
Early identification of treatment non-response utilizing the Patient Health Questionnaire (PHQ-9)
Fowler, J. C., Patriquin, M. A., Madan, A., Allen, J. G., Frueh, B. C., & Oldham, J. M. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.06.018 · Cited by 21
“…treatment innovation and research, rates of treatment non-response for individuals with disorders such as depression or schizophrenia approaches 50% of all patients (McEvoy et al., 2006; Newnham et al., 2007, 2010; Rush and Trivedi, 1995; Rush et al., 2006; Stroup et al., 2006; Thase et al., 2007).”
BackgroundUse of atypical antipsychotics for treatment-resistant major depressive disorder
Papakostas, G. I., & Shelton, R. C. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0077-3 · Cited by 26
Maneeton, B., Maneeton, N., Eurviriyanukul, & Srisurapanont, M. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s46849 · Cited by 27
Souery, D., Calati, R., Papageorgiou, K., Juven‐Wetzler, A., Gailledreau, J., Modavi, D., Sentissi, O., Pitchot, W., Papadimitriou, G. N., Dikeos, D. G., et al. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.987814 · Cited by 20
“An increasing number of reports showed no advantage in favour of switching to a different class of antidepressant in patients with MDD (Ruhe et al. 2006; Rush et al. 2006; Bschor and Baethge 2010; Souery et al. 2011a,b; Gaynes et al. 2012).”
BackgroundBrand, S. J., & Harvey, B. H. (2016) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.50 · Cited by 21
“Similarly, pre-clinical (67,68) and clinical (20,21,69) data have demonstrated venlafaxine to be equally if not more effective than SSRIs making it a popular treatment choice in patients resistant to SSRI treatment (69).”
BackgroundConséquences de l’inter-relation des systèmes monoaminergiques dans l’activité antidépressive
Tritschler, L., Gaillard, R., Gardier, A. M., David, D. J. P., & Guilloux, J. (2018) · L Encéphale · doi:10.1016/j.encep.2018.05.001 · Cited by 21
“D’autre part, un pourcenage significatif de patients résiste au traitement et/ou développe es formes récurrentes [8].”
BackgroundMoriguchi, S., Inagaki, R., Yi, L., Shibata, M., Sakagami, H., & Fukunaga, K. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02077-z · Cited by 19
Lee, D. Y., Kim, N., Park, C., Gan, S., Son, S. J., Park, R. W., & Park, B. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115817 · Cited by 19
“Depression is a severely debilitating disorder that is significantly associated with mortality, personal costs, and family burden (Kessler, 2012; Rush et al., 2006).”
Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction
Bishop, J., Chae, S. S., Patel, S. R., Moline, J., & Ellingrod, V. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.03.048 · Cited by 18
“Unfortunately, a high proportion of patients choose to discontinue their medication due to adverse effects (Bull et al., 2002a,b; Rush et al., 2006) with sexual dysfunction reported as a common bothersome outcome from these medications (Hu et al.”
The pathophysiology and management of depression in cardiac surgery patients
Vu, T., & Smith, J. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1195028 · Cited by 23
Group analysis versus individual response: The inferential limits of randomized controlled trials
Kelley, J. M., & Kaptchuk, T. J. (2010) · Contemporary Clinical Trials · doi:10.1016/j.cct.2010.07.003 · Cited by 20
“New England Journal of Medicine [10].”
Gaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.4.510 · Cited by 19
Self-citationKweon, K., & Kim, H. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.4.537 · Cited by 21
“In studies conducted in adults, some patients who were resistant to selective serotonin reuptake inhibitors (SSRIs) responded well to bupropion [5], and bupropion is reported to have a lower AEMS rate than other antidepressants [6].”
BackgroundOptimized Treatment Strategy for Depressive Disorder
Chen, P. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9271-0_11 · Cited by 23
NAZ, B., CRAIG, T. J., BROMET, E. J., FINCH, S. J., FOCHTMANN, L. J., & CARLSON, G. A. (2007) · Psychological Medicine · doi:10.1017/s0033291707000141 · Cited by 18
“In addition, there was little evidence of augmentation of AD with other medications or of direct switching from one AD to another as recent reports have noted (Rush et al. 2006; Trivedi et al. 2006).”
BackgroundMöller, H. ‐., & Maier, W. A., III (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2291-3 · Cited by 19
Mundi, J. P., Betancourt, J., Ezziddin, O., Tremayne, B., Majic, T., & Mosenifar, Z. (2012) · Journal of Intensive Care Medicine · doi:10.1177/0885066611429661 · Cited by 17
Targeting Treatment-Resistant Depression
Mathys, M. L., & Mitchell, B. G. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011426972 · Cited by 22
Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?
Fornaro, M., Aguglia, E., Dell’Osso, L., & Perugi, G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.632366 · Cited by 17
“Although not as effective as the previously introduced tricyclic antidepressant (TCA) and monoamine oxidase inhibitor (MAO-I) agents [11,12], the SSRIs, and subsequently introduced antidepressant classes, ensured appreciable remission rates compared to placebo, without the Achilles’ heel of marked unfavorable side-eff…”
BackgroundFurukawa, T. A., Kato, T., Shinagawa, Y., Miki, K., Fujita, H., Tsujino, N., Kondo, M., Inagaki, M., & Yamada, M. (2018) · Psychological Medicine · doi:10.1017/s0033291718003331 · Cited by 17
“The total score therefore ranges between 3 and 21, with higher ratings indicating greater severity (Rush et al., 2006).”
Spitz, N. A., Eyck, P. T., Nizar, K., Boes, A. D., & Trapp, N. T. (2022) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000611 · Cited by 20
Kashner, T. M., Henley, S. S., Golden, R. M., Rush, A. J., & Jarrett, R. B. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.04.004 · Cited by 18
Self-citationTreatment-Resistant Depression: An Update on Diagnosis and Management
Janicak, P. G., & Dowd, S. M. (2009) · Psychopharm Review · doi:10.1097/01.idt.0000350191.07142.ef · Cited by 17
“In this context, the results of theNational Institute ofMental Health (NIMH)-sponsored STAR*D Study are instructive.(6,16) In this trial, subjects suffered from unipolar MDD and had no history of treatment resistance.”
BackgroundResultMcClintock, S. M., Kallioniemi, E., Martin, D. M., Kim, J. U., Weisenbach, S. L., & Abbott, C. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180031 · Cited by 21
Huffman, J. C., & Alpert, J. E. (2010) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.08.009 · Cited by 19
Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition
Won, E., Park, S., Han, K.-M., Sung, S.-H., Lee, H.-Y., Paik, J., Jeon, H. J., Lee, M., Shim, S.-H., Ko, Y., et al. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.4.468 · Cited by 19
“The CANMAT, BAP, WFSBP, and Clinical Research Center for Depression guidelines referenced 3 studies including a STAR*D study, reporting that when SSRIs are not effective, switching to venlafaxine showed a 54% remission rate (3, 13, 17, 21, 70, 71).”
MethodHow Does Electroconvulsive Therapy Work?
Reti, I. M. (2015) · Wiley eBooks · doi:10.1002/9781118568323.ch7 · Cited by 18
Furman, J. L., Soyombo, A. A., Czysz, A. H., Jha, M. K., Carmody, T. J., Mason, B. L., Scherer, P. E., & Trivedi, M. H. (2018) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2018.05.001 · Cited by 21
“Evidence from the Sequenced Treatment Alternatives to Relieve Depression (STARD) clinical trial [5] suggests that of individuals receiving depression medications, over two-thirds will not achieve remission following initial treatment and nearly one-third will not attain remission even after four adequate treatment reg…”
BackgroundSelf-citationPalladium‐Catalyzed Carbo‐Oxygenation of Propargylic Amines using in Situ Tether Formation
Greenwood, P. D. G., Grenet, E., & Waser, J. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201900020 · Cited by 16
Claassen, C., Kurian, B. T., Trivedi, M. H., Grannemann, B. D., Tuli, E., Pipes, R., Preston, A. M., & Flood, A. (2008) · Contemporary Clinical Trials · doi:10.1016/j.cct.2008.08.001 · Cited by 16
“Also like Project IMPACTS, two of these prior studies [21, 23] made use of telephone-based assessments to gather the primary outcomes of interest, while Trivedi et al.”
MethodSelf-citationGlucocorticoid Receptor Genetic Variants and Response to Fluoxetine in Major Depressive Disorder
Nouraei, H., Firouzabadi, N., Mandegary, A., Zomorrodian, K., Bahramali, E., Shayesteh, M. R. H., & Ansari, S. (2017) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.16120322 · Cited by 15
Nitrous Oxide Induces Prominent Cell Proliferation in Adult Rat Hippocampal Dentate Gyrus
Chamaa, F., Bahmad, H. F., Makkawi, A.-K., Chalhoub, R., Al–Chaer, E. D., Bikhazi, G. B., Nahas, Z. H., & Abou-Kheir, W. G. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00135 · Cited by 17
“Despite the usefulness of the currently available antidepressant therapies (UK ECT Review Group, 2003; Mayberg et al., 2005), more than 20% of patients with depression still suffer from a virulent subtype of treatment-resistant depression (TRD; Rush et al., 2006a,b; Mrazek et al., 2014).”
BackgroundValenstein, M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1484 · Cited by 15
Seetasith, A., Greene, M., Hartry, A., & Burudpakdee, C. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1484373 · Cited by 15
Goerigk, S. A., Padberg, F., Chekroud, A. M., Kambeitz, J. P., Bühner, M., & Brunoni, A. R. (2021) · Brain stimulation · doi:10.1016/j.brs.2021.05.008 · Cited by 20
“Major depressive disorder (MDD) is a highly prevalent disorder with high refractoriness rates [1,2].”
BackgroundBarnes, R., Skvarc, D., Fitzgerald, P. B., Berk, M., Dean, O. M., Dodd, S., Schriemer, T., & Singh, A. B. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110820 · Cited by 18
Yeh, Y., Chen, C.-J., Jang, F.-L., Kuo, S.-C., Chen, C., Liang, C., Ho, P., Yen, C.-H., Shyu, J., Wan, F.-J., et al. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.11.017 · Cited by 17
“In general, only one third of patients with MDD patients achieve remission after an antidepressant monotherapy trial (Rush et al., 2006).”
BackgroundEllis, A. R., Dusetzina, S. B., Hansen, R. A., Gaynes, B. N., Farley, J. F., & Stürmer, T. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3396 · Cited by 17
Gudayol‐Ferré, E., Herrera‐Guzmán, I., Camarena, B., Cortés‐Penagos, C., Herrera‐Abarca, J. E., Martínez‐Medina, P., Asbún‐Bojalil, J., Lira‐Islas, Y., Reyes‐Ponce, C., & Guàrdia‐Olmos, J. (2012) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2267 · Cited by 17
“Major depressive disorder (MDD) is usually treated with antidepressant drugs, and among these drugs, the selective serotonin reuptake inhibitors (SSRI) are widely prescribed because of their effectiveness, relatively low toxicity, and tolerability (Stahl, 2002; Rush et al., 2006).”
BackgroundTreatment Options for the Patient Who Does Not Respond Well to Initial Antidepressant Therapy
Preskorn, S. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000351880.30013.2a · Cited by 15
Wang, H., Wang, K., Zhang, W., Zhao, W.-F., Yang, X., Wang, L., Mao, P., Sun, Z., Xue, Q., Jia, Y., et al. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000589 · Cited by 15
“The current anti-depression medications and psychotherapeutic interventions are partly effective in treating depression.([3-9]) And those antidepressants show unwanted side effects, including nausea, diarrhea, fatigue, and dizziness.”
BackgroundBruder, G. E., Stewart, J. W., Schaller, J. D., & McGrath, P. J. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2007.04.011 · Cited by 16
Self-citationPositioning rTMS Within a Sequential Treatment Algorithm of Depression
Kaster, T. S., & Blumberger, D. M. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240604 · Cited by 16
Sussman, N. (2007) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v09n0501 · Cited by 14
“Robust clinical evidence documents the value of changing the treatment strategy following failure of an adequate trial of an initial medication.(17,29) It is important to note that because there were too few patients who accepted randomization to both the switch and augmentation options, STAR*D will not be able to dir…”
BackgroundMethodResultInfluentialBabcock, T., Dirks, B., Adeyi, B., & Scheckner, B. (2012) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-13-18 · Cited by 14
“, depression treatment) for a patient to be switched to a different medication within the same class [6,7].”
BackgroundFurukawa, T. A., Debray, T. P. A., Akechi, T., Yamada, M., Kato, T., Seo, M., & Efthimiou, O. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.141 · Cited by 16
Engelmann, J., Wagner, S., Solheid, A., Herzog, D. P., Dreimüller, N., Müller, M. B., Tadić, A., Hiemke, C., & Lieb, K. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001312 · Cited by 16
van Dam, W. O., & Chrysikou, E. G. (2021) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-020-00830-4 · Cited by 17
Key considerations in the pharmacological management of treatment-resistant depression
Yavi, M., Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1951225 · Cited by 15
“into treatment groups with bupropion, sertraline, or venlafaxine for 14 weeks [20].”
MethodChen, B., Jiao, Z., Shen, T., Fan, R. G., Chen, Y., & Xu, Z. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04791-z · Cited by 15
“Selective serotonin reuptake inhibitors (SSRIs) are the common first-line agents used to treat major depressive disorder (MDD) [2, 3], but over two-third of the patients who received SSRIs treatment failed to achieve symptom remission [4].”
BackgroundMagnetic Seizure Therapy for the Treatment of Depression
Lisanby, S. H., & Peterchev, A. V. (2007) · KARGER eBooks · doi:10.1159/000101036 · Cited by 15
Gaynes, B., Farley, J., Dusetzina, S., Ellis, A., Hansen, R. A., Miller, W., & Stürmer, T. (2011) · Depression and Anxiety · doi:10.1002/da.20898 · Cited by 12
“Initial STAR D outcome analyses at level 2 found no significant differences in remission or response rates among patients receiving medication augmentation[38] or among patients who switched medication.[39] However, if one considers symptom clusters as potential effect modifiers, some potential differences among treat…”
BackgroundHenry, C. A., Shervin, D., Neumeyer, A. M., Steingard, R. J., Spybrook, J. K., Choueiri, R., & Bauman, M. L. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.037 · Cited by 14
“…treatment failure has been advocated in the treatment of adults with major depression (Nierenberg et al. 2007) as there are multiple studies supporting the potential usefulness of a second trial in this population (Brown and Harrison1995; Joffe et al. 1996; Thase et al. 1997; Rush et al. 2006).”
InfluentialBeta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients
Firouzabadi, N., Raeesi, R., Zomorrodian, K., Bahramali, E., & Yavarian, I. (2017) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3w31f · Cited by 15
“Among the antidepressants, the SSRIs are common first line treatments, especially due to their minimal adverse effects and good tolerability (27).”
BackgroundBiomarkers in Major Depressive Disorder: The Role of Mass Spectrometry
Woods, A. G., Iosifescu, D. V., & Darie, C. C. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-06068-2_27 · Cited by 17
“Unfortunately, partial or suboptimal response to treatment occurs commonly in MDD, and only 30–40 % of patients receiving treatment will fully remit (achieving near-complete resolution of symptoms) [ 14 – 17 ].”
BackgroundAntidepressants are not all created equal
Parikh, S. V. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60047-7 · Cited by 14
Kim, S., LeBlanc, A. J., & Michalopoulos, C. (2009) · SSRN Electronic Journal · Cited by 13
Pandina, G., Revicki, D. A., Kleinman, L., Turkoz, I., Wu, J., Kujawa, M. J., Mahmoud, R. A., & Gharabawi, G. M. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.02.019 · Cited by 15
“Further, patientrated scales, such as the Patient Global Improvement Scale (PGIS), the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Endicott et al., 1993), the Inventory of Depressive Symptomatology (Rush et al., 2006a), and the Sheehan Disability Scale (SDS) may not fully reflect the troublesom…”
BackgroundInfluentialFirouzabadi, N., Navabzadeh, N., Sarani, E. M., & Haghnegahdar, M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s250141 · Cited by 14
Kessler, R. C., Furukawa, T. A., Kato, T., Luedtke, A. R., Petukhova, M. V., Sadikova, E., & Sampson, N. A. (2021) · Psychological Medicine · doi:10.1017/s0033291721000027 · Cited by 14
“About 30% of treated cases remit after a full course of evidence-based treatment and 70% after several such courses (Rush et al., 2006a).”
BackgroundMethodSzmulewicz, A., Wanis, K. N., Perlis, R. H., Hernández–Díaz, S., Öngür, D., & Hernán, M. Á. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.09.028 · Cited by 15
Commentary: Use of Treatment Algorithms for Depression
Trivedi, M. H., Fava, M., Marangell, L. B., Osser, D. N., & Shelton, R. C. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0506 · Cited by 16
Self-citationEvaluation of the efficacy and safety of vilazodone for treating major depressive disorder
Yu, S., Zhang, X., Wu, L., Wan, D., Liu, R., Dong, Z., & Chen, M. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s87968 · Cited by 17
Pandina, G., Garibaldi, G., Revicki, D., Kleinman, L., Turkoz, I., Kujawa, M., & Mahmoud, R. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283320667 · Cited by 9
“Numerous studies have evaluated pharmacologic strategies designed to improve therapeutic response in those with residual symptoms of depression (Joffe et al., 1996; Zarate et al., 1996; Thase et al., 1997; Spier, 1998; Fatemi et al., 1999; Shelton, 1999; Appelberg et al., 2001; Marangell, 2001; Fava et al., 2003a; Alp…”
BackgroundHansen, R., Dusetzina, S., Ellis, A., Stürmer, T., Farley, J., & Gaynes, B. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2011.10.001 · Cited by 12
“, combining) existing treatment with a second medication are two possible treatment strategies when first-step treatment fails [5–8].”
BackgroundMethodTreatment-Resistant Depression: Managed Care Considerations
Tierney, J. G. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.s6-a.2 · Cited by 16
“Recent results from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study showed that among patients who did not achieve remission with initial therapy, approximately one third achieved remission by augmentation with a second agent and about one fourth achieved remission by switching to a different…”
BackgroundResultVilazodone for the Treatment of Depression
Lindsey, W. T. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p772 · Cited by 13
Multi-state neural dynamics encode antidepressant response: Fusion of resting and task networks
Peng, Y., (260119), Y. Y., Zhou, N., Fan, X., Jiang, L., He, G., Li, C., Yi, C., Yao, D., Shi, K., et al. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.111999 · Cited by 14
Fang, C., Hayashi, S., Du, X., Cai, X., Deng, B., Zheng, H., Ishido, S., Tsutsui, H., & Sheng, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-86659-4 · Cited by 12
Siemsen, B. M., Franco, D., & Lobo, M. K. (2022) · Neuroscience Research · doi:10.1016/j.neures.2022.12.014 · Cited by 14
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
“In the Level 2 treatments of the STAR*D, about 25% of patients who received venlafaxine achieved remission compared to about 18% of patients who received sertraline achieving remission [8].”
InfluentialOgg, M. C., Lansdell, B., Franks, H. T., Hughes, A. C., Lee, J., Nolen, H. G., Shirinifard, A., & Schwarz, L. A. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116687 · Cited by 12
Getting the balance right: Established and emerging therapies for major depressive disorders
Vezmar (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s10485 · Cited by 16
“After switching from cit-alopram, bupropion SR was as effective as sertraline and venlafaxine XR. 113 The drug was as effective as buspirone in augmentation of citalopram (see Table 1).”
Ge, R., Gregory, E., Wang, J., Ainsworth, N. J., Jian, W., Yang, C., Wang, G., & Vila‐Rodriguez, F. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.02.051 · Cited by 14
Cenik, B., Palka, J. M., Thompson, B. M., McDonald, J. G., Tamminga, C. A., Cenik, C., & Brown, E. S. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01903-3 · Cited by 12
“Current treatments are only partially effective; about one third of patients with MDD fail to achieve remission with first or second line treatments [5].”
BackgroundYeh, Y., Kuo, S.-C., Chen, C., Liang, C., Ho, P., Yen, C.-H., Chen, T., Shyu, J., Wan, F.-J., Lu, R., et al. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.05.012 · Cited by 12
“Although antidepressants are effective treatments for MDD, only two thirds of patients respond and only one third of patients achieve remission (Rush et al., 2006).”
BackgroundHsu, J. H., Mulsant, B. H., Lenze, E. J., Karp, J. F., Lavretsky, H., Roose, S. P., Reynolds, C. F., & Blumberger, D. M. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.04.015 · Cited by 12
Management of Treatment-Resistant Posttraumatic Stress Disorder
Starke, J., & Stein, D. J. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0130-0 · Cited by 12
Gadad, B. S., Raj, P., Jha, M. K., Carmody, T. J., Dozmorov, I. M., Mayes, T. L., Wakeland, E. K., & Trivedi, M. H. (2018) · Complex Psychiatry · doi:10.1159/000487321 · Cited by 13
Self-citationJha, M., South, C., Trivedi, J., Minhajuddin, A., Rush, A., & Trivedi, M. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz011 · Cited by 12
Self-citationThase, M. E. (2009) · CNS Spectrums · doi:10.1017/s1092852900003515 · Cited by 12
Self-citationSchroer, S., & MacPherson, H. (2009) · Trials · doi:10.1186/1745-6215-10-3 · Cited by 14
Fabrazzo, M., Perris, F., Monteleone, P., Esposito, G., Catapano, F., & Maj, M. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.06.006 · Cited by 13
Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder
Sato, Y., Yasui‐Furukori, N., Nakagami, T., Saito, M., & Kaneko, S. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.12.018 · Cited by 12
Antidepressants in Adult Suicides in New York City
Leon, A. C., Marzuk, P. M., Tardiff, K. J., Bucciarelli, A., Stajić, M., Piper, T. M., & Galea, S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0911 · Cited by 13
STAR*D: The Results Begin to Roll in
Menza, M. A. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1123 · Cited by 19
Identification and treatment of depression in minority populations
Dejesus, S. A., Diaz, V. A., Gonsalves, W. C., & Carek, P. J. (2011) · The International Journal of Psychiatry in Medicine · doi:10.2190/pm.42.1.e · Cited by 11
Dagher, M., Cahill, C. M., & Andrews, A. M. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100046 · Cited by 16
Liu, Y., & Kou, Z. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100610 · Cited by 17
“…systems in the pathophysiology of TRD. Thematic evolution maps demonstrate the coexistence of foundational research (e.g., fluoxetine, serotonin) (21,22) with emerging therapies (DBS, VNS) (8,23), supporting a hybrid model of innovation that bridges basic science and clinical practice.”
Li, X., Guo, X., Fan, X., Feng, T., Wang, C., Yao, Z., Xu, X., Chen, Z., Wang, H., Xie, S., et al. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.11.010 · Cited by 14
Nierenberg, A. A., Trivedi, M. H., Gaynes, B. N., Mitchell, J. R., Davis, L. L., Husain, M. M., Wisniewski, S. R., Fava, M., Warden, D., Luther, J. F., et al. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670903001885 · Cited by 11
“In STAR*D, those who did not reach remission (score 55 on the 16-item Quick Inventory of Depressive Symptomatology Self-Rated (QIDS-SR16)) with or who were intolerant to citalopram [4 7] and moved on to a second monotherapy treatment (medication switch) [8] had a remission rate of approximately 20%.”
BackgroundSelf-citation
Metadata
- Authors
- Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., Shores-Wilson, K., Niederehe, G., & Fava, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- New York State Psychiatric Institute (US)
- Massachusetts General Hospital (US)
- National Institute of Mental Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1231-1242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140787893
- Cited by
- 1,033
- References
- 44
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 28 · 2021: 46 · 2020: 43 · 2019: 54 · 2018: 51 · 2017: 35 · 2016: 42 · 2015: 45 · 2014: 46 · 2013: 45 · 2012: 43
- FWCI
- 66.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, antidepressant switching, bupropion, sertraline, venlafaxine, treatment-resistant depression, symptom remission, antidepressant response, outpatients
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Female, Humans, Male, Remission Induction, Time Factors, Bupropion, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.